{"gene":"BPNT2","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":2008,"finding":"gPAPP (BPNT2) is a Golgi-resident PAP 3'-phosphatase that hydrolyzes 3'-phosphoadenosine 5'-phosphate (PAP), the byproduct of sulfotransferase reactions, to AMP; its inactivation in mice leads to neonatal lethality, lung abnormalities, dwarfism with aberrant cartilage morphology, undersulfated chondroitin, and perturbations in heparan sulfate species, consistent with a role in clearing the nucleotide product of sulfotransferases within the Golgi to support glycosaminoglycan sulfation. The enzyme activity is potently inhibited by lithium in vitro.","method":"Mouse knockout model with biochemical analysis of GAG sulfation (chondroitin and heparan sulfate measurements), in vitro lithium inhibition assay, subcellular localization studies","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro enzymatic assay, mouse KO with defined phenotype, biochemical rescue experiments, multiple orthogonal methods in a single study","pmids":["18695242"],"is_preprint":false},{"year":2011,"finding":"Homozygous missense mutations in IMPAD1 (BPNT2) affecting residues in or adjacent to the phosphatase active site cause chondrodysplasia with brachydactyly, congenital joint dislocations, cleft palate, and facial dysmorphism in humans, consistent with impaired PAP hydrolysis and defective proteoglycan sulfation.","method":"Whole-exome sequencing of affected individuals, identification of active-site mutations, structural prediction of mutation impact; corroborated by mouse Impad1 inactivation data showing impaired proteoglycan sulfation","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetics linked to active-site residues, replicated across multiple unrelated families, corroborated by prior mouse KO data","pmids":["21549340"],"is_preprint":false},{"year":2012,"finding":"Recombinant gPAPP (BPNT2) was used to couple sulfotransferase reactions in vitro by releasing the 3'-phosphate from PAP, enabling determination of enzyme kinetics (Michaelis-Menten constants) and demonstrating PAP product inhibition removal for sulfotransferases. This confirms gPAPP specifically acts as a PAP 3'-phosphatase and its enzymatic rate is quantifiable for coupled assay design.","method":"In vitro enzyme kinetics assay (malachite green phosphate detection), radioisotope validation assay, coupled enzyme reaction with recombinant gPAPP","journal":"Analytical biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with kinetic characterization and orthogonal radioisotope validation, single lab","pmids":["22289690"],"is_preprint":false},{"year":2021,"finding":"The catalytic activity of BPNT2 is required for GAG sulfation in vitro: a catalytic-dead Bpnt2 construct (D108A) fails to rescue impaired intracellular and secreted sulfated GAGs (including chondroitin-4-sulfate) in Bpnt2-KO mouse embryonic fibroblasts. Human chondrodysplasia-causing missense mutations adjacent to the catalytic site recapitulate GAG sulfation defects in MEFs. Lithium inhibits GAG sulfation in a BPNT2-dependent manner.","method":"Catalytic-dead mutagenesis (D108A) rescue experiment in Bpnt2-KO MEFs, disease-associated missense mutation functional assay, lithium treatment of MEFs with GAG sulfation quantification","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — active-site mutagenesis with functional rescue assay, disease mutation validation, chemical inhibitor corroboration; single lab but multiple orthogonal approaches","pmids":["34634304"],"is_preprint":false},{"year":2020,"finding":"IMPAD1 (BPNT2) drives lung cancer invasion and metastasis by enhancing Golgi-mediated secretion; this pro-invasive effect is suppressed by therapeutically inhibiting matrix metalloproteases (MMPs), placing IMPAD1-mediated Golgi secretion upstream of MMP-dependent invasion.","method":"Gain-of-function invasion screen, in vitro invasion assays, in vivo metastasis models, MMP inhibitor treatment","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function screen validated by in vitro and in vivo assays with pharmacological epistasis (MMP inhibitor), single lab","pmids":["32753652"],"is_preprint":false},{"year":2020,"finding":"IMPAD1 (BPNT2) promotes lung cancer metastasis by inhibiting mitochondrial Complex I activity, reducing mitochondrial ROS levels, and increasing intracellular AMP, which activates the AMPK-Notch1-HEY1 signaling pathway. AMP acts as an ADORA1 agonist, and ADORA1 inhibition reduces pAMPK and HEY1 expression in IMPAD1-overexpressing cells.","method":"IMPAD1 knockdown and overexpression in vitro/in vivo, mitochondrial Complex I activity assay, ROS measurement, pAMPK/Notch1/HEY1 western blotting, ADORA1 inhibitor treatment","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays (Complex I, ROS, signaling pathway), pharmacological epistasis, but non-canonical function contradicts established Golgi-PAP hydrolysis role; single lab","pmids":["32417395"],"is_preprint":false},{"year":2022,"finding":"Impad1 is a direct transcriptional target of the epithelial miRNAs miR-200 and miR~96, which suppress its expression; it is de-repressed during epithelial-to-mesenchymal transition (EMT). Impad1 modulates Golgi apparatus morphology and vesicular trafficking through a direct interaction with the trafficking protein Syt11, altering the extracellular matrix and tumor microenvironment to promote invasion and metastasis. Inhibiting either Impad1 or Syt11 disrupts the cancer cell secretome and reverses the invasive phenotype.","method":"miRNA target validation (miR-200/miR-96), co-immunoprecipitation or interaction assay with Syt11, Golgi morphology imaging, secretome analysis, in vitro invasion assays, in vivo metastasis models","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — miRNA regulation validated, protein-protein interaction identified, Golgi morphology and secretome measured; single lab with multiple orthogonal methods","pmids":["36170810"],"is_preprint":false},{"year":2017,"finding":"IMPAD1 (gPAPP/BPNT2) converts PAP to AMP in vitro, enabling coupling to the AMP-Glo bioluminescence detection system to measure sulfotransferase activities; this confirms PAP-to-AMP conversion as the specific enzymatic activity of IMPAD1.","method":"Enzyme-coupled in vitro biochemical assay using recombinant IMPAD1 to convert PAP to AMP, bioluminescent detection","journal":"Assay and drug development technologies","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro enzymatic reconstitution, single lab, single method","pmids":["29120675"],"is_preprint":false},{"year":2025,"finding":"BPNT2 participates in a mammalian rapid tRNA decay (mRTD) pathway for tRNA quality control under heat stress, alongside Bpnt1 and Xrn1/Xrn2 exonucleases; intracellular pAp level control by Bpnt1/Bpnt2 is required for selective degradation of tRNALeu(CAG) under heat stress.","method":"Genetic deletion of Thumpd1 in NIH/3T3 cells, tRNA decay assays under heat stress, measurement of pAp levels, pathway epistasis with Xrn1/Xrn2","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic epistasis with defined molecular pathway in mammalian cells, but BPNT2 is one of two closely related enzymes implicated collectively; single lab","pmids":["40595590"],"is_preprint":false}],"current_model":"BPNT2 (gPAPP/IMPAD1) is a Golgi-resident, magnesium-dependent, lithium-inhibited 3'-phosphatase that hydrolyzes PAP (3'-phosphoadenosine 5'-phosphate), the sulfotransferase byproduct, to AMP, thereby clearing product inhibition within the Golgi to sustain glycosaminoglycan (particularly chondroitin-4-sulfate) sulfation; loss of its catalytic activity—whether by genetic KO, catalytic-dead mutation (D108A), disease-causing missense mutations, or lithium inhibition—impairs GAG sulfation and causes skeletal dysplasia, while in cancer contexts BPNT2 also modulates Golgi morphology and vesicular secretion through interaction with Syt11, is regulated by miR-200/miR-96 during EMT, and has additionally been implicated in a mammalian tRNA quality-control decay pathway."},"narrative":{"mechanistic_narrative":"BPNT2 (gPAPP/IMPAD1) is a Golgi-resident, magnesium-dependent, lithium-inhibited 3'-phosphatase that hydrolyzes 3'-phosphoadenosine 5'-phosphate (PAP)—the byproduct of sulfotransferase reactions—to AMP, thereby relieving product inhibition and sustaining glycosaminoglycan sulfation [PMID:18695242, PMID:22289690, PMID:29120675]. This catalytic activity is essential for GAG sulfation: a catalytic-dead D108A construct fails to rescue intracellular and secreted sulfated GAGs (including chondroitin-4-sulfate) in Bpnt2-KO fibroblasts, and lithium inhibits sulfation in a BPNT2-dependent manner [PMID:34634304]. Loss of this function is physiologically consequential—murine inactivation produces neonatal lethality, dwarfism, aberrant cartilage, and undersulfated chondroitin [PMID:18695242], and homozygous active-site missense mutations in humans cause chondrodysplasia with brachydactyly, joint dislocations, cleft palate, and facial dysmorphism, with disease alleles recapitulating the GAG defect in cells [PMID:21549340, PMID:34634304]. Beyond its canonical sulfation role, BPNT2 drives lung cancer invasion and metastasis by enhancing Golgi-mediated secretion upstream of MMP-dependent invasion, acting through a direct interaction with the trafficking protein Syt11 to remodel Golgi morphology and the secretome, and is de-repressed during EMT upon loss of miR-200/miR-96 suppression [PMID:32753652, PMID:36170810]. BPNT2-dependent control of intracellular PAP levels has additionally been implicated in a mammalian rapid tRNA decay pathway under heat stress, acting alongside Bpnt1 and Xrn1/Xrn2 [PMID:40595590].","teleology":[{"year":2008,"claim":"Establishing where PAP, the inhibitory sulfotransferase byproduct, is cleared and why it matters answered whether a dedicated Golgi enzyme links nucleotide turnover to glycosaminoglycan sulfation.","evidence":"Mouse knockout with GAG sulfation biochemistry, subcellular localization, and in vitro lithium inhibition assay","pmids":["18695242"],"confidence":"High","gaps":["Structural basis of catalysis and lithium sensitivity not resolved","Mechanism connecting undersulfation to skeletal phenotype not detailed"]},{"year":2011,"claim":"Whether BPNT2 catalytic function is required in humans was answered by linking active-site mutations to a defined skeletal disease.","evidence":"Whole-exome sequencing of affected families with active-site mutation identification, corroborated by mouse KO data","pmids":["21549340"],"confidence":"High","gaps":["Genotype-phenotype severity correlation across mutations not established","Direct enzymatic deficit of patient alleles not measured in this study"]},{"year":2012,"claim":"Reconstituting the enzyme in vitro confirmed PAP-3'-phosphatase identity and quantified its kinetics, enabling its use to relieve product inhibition of sulfotransferases.","evidence":"In vitro coupled enzyme kinetics with malachite green phosphate detection and radioisotope validation","pmids":["22289690"],"confidence":"High","gaps":["Substrate specificity relative to related phosphatases not delineated","In-cell kinetics not addressed"]},{"year":2017,"claim":"An orthogonal assay coupling PAP-to-AMP conversion confirmed AMP as the reaction product and supported sulfotransferase activity measurement.","evidence":"Enzyme-coupled bioluminescent (AMP-Glo) assay with recombinant IMPAD1","pmids":["29120675"],"confidence":"Medium","gaps":["Single method, single lab","No new physiological insight beyond confirming product identity"]},{"year":2020,"claim":"Whether BPNT2 has roles beyond skeletal biology was addressed by showing it promotes lung cancer invasion via Golgi secretion upstream of MMPs.","evidence":"Gain-of-function invasion screen, in vitro/in vivo metastasis assays, MMP inhibitor epistasis","pmids":["32753652"],"confidence":"Medium","gaps":["Whether catalytic activity is required for the pro-invasive effect not tested","Direct secreted cargoes not identified"]},{"year":2020,"claim":"A metabolic-signaling axis for IMPAD1 in cancer was proposed, linking AMP accumulation to AMPK-Notch1-HEY1 signaling and Complex I inhibition.","evidence":"Knockdown/overexpression with Complex I activity, ROS, signaling western blots, and ADORA1 inhibitor treatment","pmids":["32417395"],"confidence":"Medium","gaps":["Non-canonical mechanism diverges from the established Golgi-PAP hydrolysis role and not independently confirmed","Direct mechanism by which a Golgi phosphatase inhibits mitochondrial Complex I unclear"]},{"year":2022,"claim":"The trafficking mechanism and upstream regulation of IMPAD1 in cancer were defined through a direct Syt11 interaction and miR-200/miR-96 control during EMT.","evidence":"miRNA target validation, Syt11 interaction assay, Golgi morphology imaging, secretome analysis, in vitro/in vivo metastasis models","pmids":["36170810"],"confidence":"Medium","gaps":["Whether the Syt11 interaction depends on BPNT2 catalytic activity not resolved","Structural details of the BPNT2-Syt11 interface unknown"]},{"year":2025,"claim":"A new role for BPNT2 in RNA quality control was identified, implicating PAP-level control in heat-stress tRNA decay.","evidence":"Thumpd1 deletion in NIH/3T3 cells, tRNA decay assays under heat stress, pAp measurement, Xrn1/Xrn2 pathway epistasis","pmids":["40595590"],"confidence":"Medium","gaps":["BPNT2 implicated collectively with Bpnt1, so its individual contribution is unresolved","Mechanistic link between PAP levels and selective tRNA degradation not detailed"]},{"year":null,"claim":"Whether the Golgi sulfation function, the secretory/Syt11 cancer function, and the tRNA-decay function reflect one unified PAP-clearing activity or distinct catalysis-independent roles remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of the human enzyme reported in the corpus","Catalytic dependence of the cancer and tRNA-decay roles not directly tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,3,7]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0,6]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,3]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[4,6]}],"complexes":[],"partners":["SYT11"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NX62","full_name":"Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase","aliases":["3'(2'), 5'-bisphosphate nucleotidase 2","Inositol monophosphatase domain-containing protein 1","Myo-inositol monophosphatase A3","Phosphoadenosine phosphate 3'-nucleotidase"],"length_aa":359,"mass_kda":38.7,"function":"Exhibits 3'-nucleotidase activity toward adenosine 3',5'-bisphosphate (PAP), namely hydrolyzes adenosine 3',5'-bisphosphate into adenosine 5'-monophosphate (AMP) and a phosphate. May play a role in the formation of skeletal elements derived through endochondral ossification, possibly by clearing adenosine 3',5'-bisphosphate produced by Golgi sulfotransferases during glycosaminoglycan sulfation. Has no activity toward 3'-phosphoadenosine 5'-phosphosulfate (PAPS) or inositol phosphate (IP) substrates including I(1)P, I(1,4)P2, I(1,3,4)P3, I(1,4,5)P3 and I(1,3,4,5)P4","subcellular_location":"Golgi apparatus; Golgi apparatus, trans-Golgi network membrane","url":"https://www.uniprot.org/uniprotkb/Q9NX62/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BPNT2","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"OCRL","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BPNT2","total_profiled":1310},"omim":[],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Golgi apparatus","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BPNT2"},"hgnc":{"alias_symbol":["FLJ20421","IMPA3","gPAPP"],"prev_symbol":["IMPAD1"]},"alphafold":{"accession":"Q9NX62","domains":[{"cath_id":"3.30.540.10","chopping":"59-225","consensus_level":"medium","plddt":95.2692,"start":59,"end":225},{"cath_id":"3.40.190.80","chopping":"227-348","consensus_level":"medium","plddt":93.8366,"start":227,"end":348}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NX62","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NX62-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NX62-F1-predicted_aligned_error_v6.png","plddt_mean":87.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BPNT2","jax_strain_url":"https://www.jax.org/strain/search?query=BPNT2"},"sequence":{"accession":"Q9NX62","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NX62.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NX62/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NX62"}},"corpus_meta":[{"pmid":"21549340","id":"PMC_21549340","title":"Chondrodysplasia and abnormal joint development associated with mutations in IMPAD1, encoding the Golgi-resident nucleotide phosphatase, gPAPP.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21549340","citation_count":71,"is_preprint":false},{"pmid":"34043989","id":"PMC_34043989","title":"Therapeutic potential of AMPK signaling targeting in lung cancer: Advances, challenges and future prospects.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34043989","citation_count":70,"is_preprint":false},{"pmid":"18695242","id":"PMC_18695242","title":"A role for a lithium-inhibited Golgi nucleotidase in skeletal development and sulfation.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18695242","citation_count":60,"is_preprint":false},{"pmid":"24662924","id":"PMC_24662924","title":"Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas.","date":"2014","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24662924","citation_count":59,"is_preprint":false},{"pmid":"32753652","id":"PMC_32753652","title":"IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32753652","citation_count":35,"is_preprint":false},{"pmid":"29120675","id":"PMC_29120675","title":"Utility of Adenosine Monophosphate Detection System for Monitoring the Activities of Diverse Enzyme Reactions.","date":"2017","source":"Assay and drug development technologies","url":"https://pubmed.ncbi.nlm.nih.gov/29120675","citation_count":23,"is_preprint":false},{"pmid":"36650118","id":"PMC_36650118","title":"LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing.","date":"2023","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36650118","citation_count":21,"is_preprint":false},{"pmid":"23479625","id":"PMC_23479625","title":"Role for cytoplasmic nucleotide hydrolysis in hepatic function and protein synthesis.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23479625","citation_count":20,"is_preprint":false},{"pmid":"32417395","id":"PMC_32417395","title":"IMPAD1 functions as mitochondrial electron transport inhibitor that prevents ROS production and promotes lung cancer metastasis through the AMPK-Notch1-HEY1 pathway.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32417395","citation_count":19,"is_preprint":false},{"pmid":"22289690","id":"PMC_22289690","title":"Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays.","date":"2012","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22289690","citation_count":13,"is_preprint":false},{"pmid":"30283018","id":"PMC_30283018","title":"Glycerophosphatidylcholine PC(36:1) absence and 3'-phosphoadenylate (pAp) accumulation are hallmarks of the human glioma metabolome.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30283018","citation_count":13,"is_preprint":false},{"pmid":"36170810","id":"PMC_36170810","title":"Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36170810","citation_count":10,"is_preprint":false},{"pmid":"34634304","id":"PMC_34634304","title":"Sulfation of glycosaminoglycans depends on the catalytic activity of lithium-inhibited phosphatase BPNT2 in vitro.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34634304","citation_count":8,"is_preprint":false},{"pmid":"30914425","id":"PMC_30914425","title":"Identification of a Rat Mammary Tumor Risk Locus That Is Syntenic with the Commonly Amplified 8q12.1 and 8q22.1 Regions in Human Breast Cancer Patients.","date":"2019","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/30914425","citation_count":8,"is_preprint":false},{"pmid":"35872387","id":"PMC_35872387","title":"An imputation-based genome-wide association study for growth and fatness traits in Sujiang pigs.","date":"2022","source":"Animal : an international journal of animal bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/35872387","citation_count":8,"is_preprint":false},{"pmid":"24309248","id":"PMC_24309248","title":"Tissue-specific regulation of 3'-nucleotide hydrolysis and nucleolar architecture.","date":"2013","source":"Advances in biological regulation","url":"https://pubmed.ncbi.nlm.nih.gov/24309248","citation_count":7,"is_preprint":false},{"pmid":"30865697","id":"PMC_30865697","title":"Testing the Cre-mediated genetic switch for the generation of conditional knock-in mice.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30865697","citation_count":6,"is_preprint":false},{"pmid":"37875969","id":"PMC_37875969","title":"Genetic testing and diagnostic strategies of fetal skeletal dysplasia: a preliminary study in Wuhan, China.","date":"2023","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37875969","citation_count":6,"is_preprint":false},{"pmid":"38464823","id":"PMC_38464823","title":"Proteomics-based Model for Predicting the Risk of Brain Metastasis in Patients with Resected Lung Adenocarcinoma carrying the EGFR Mutation.","date":"2024","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38464823","citation_count":4,"is_preprint":false},{"pmid":"40595590","id":"PMC_40595590","title":"Mammalian tRNA acetylation determines translation efficiency and tRNA quality control.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40595590","citation_count":3,"is_preprint":false},{"pmid":"34989141","id":"PMC_34989141","title":"Fetal presentation of chondrodysplasia with joint dislocations, GPAPP type, caused by novel biallelic IMPAD1 variants.","date":"2022","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/34989141","citation_count":1,"is_preprint":false},{"pmid":"40451486","id":"PMC_40451486","title":"Systematic Mendelian randomization of the human plasma proteome to identify therapeutic targets linking aging and frailty to perioperative delirium.","date":"2025","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/40451486","citation_count":1,"is_preprint":false},{"pmid":"41057762","id":"PMC_41057762","title":"Selective sweeps for mutations increasing height impede identification of causative mutations for fertility and other correlated traits in cattle.","date":"2025","source":"Genetics, selection, evolution : GSE","url":"https://pubmed.ncbi.nlm.nih.gov/41057762","citation_count":1,"is_preprint":false},{"pmid":"40777826","id":"PMC_40777826","title":"MicroRNA analysis of porcine muscle tissue involved in phosphoinositol metabolism.","date":"2025","source":"Frontiers in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/40777826","citation_count":0,"is_preprint":false},{"pmid":"42094029","id":"PMC_42094029","title":"Genetic Skeletal Disorders with Defects in Glycosaminoglycan Biosynthesis.","date":"2026","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/42094029","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15181,"output_tokens":2714,"usd":0.043126,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9986,"output_tokens":2876,"usd":0.060915,"stage2_stop_reason":"end_turn"},"total_usd":0.104041,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"gPAPP (BPNT2) is a Golgi-resident PAP 3'-phosphatase that hydrolyzes 3'-phosphoadenosine 5'-phosphate (PAP), the byproduct of sulfotransferase reactions, to AMP; its inactivation in mice leads to neonatal lethality, lung abnormalities, dwarfism with aberrant cartilage morphology, undersulfated chondroitin, and perturbations in heparan sulfate species, consistent with a role in clearing the nucleotide product of sulfotransferases within the Golgi to support glycosaminoglycan sulfation. The enzyme activity is potently inhibited by lithium in vitro.\",\n      \"method\": \"Mouse knockout model with biochemical analysis of GAG sulfation (chondroitin and heparan sulfate measurements), in vitro lithium inhibition assay, subcellular localization studies\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro enzymatic assay, mouse KO with defined phenotype, biochemical rescue experiments, multiple orthogonal methods in a single study\",\n      \"pmids\": [\"18695242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Homozygous missense mutations in IMPAD1 (BPNT2) affecting residues in or adjacent to the phosphatase active site cause chondrodysplasia with brachydactyly, congenital joint dislocations, cleft palate, and facial dysmorphism in humans, consistent with impaired PAP hydrolysis and defective proteoglycan sulfation.\",\n      \"method\": \"Whole-exome sequencing of affected individuals, identification of active-site mutations, structural prediction of mutation impact; corroborated by mouse Impad1 inactivation data showing impaired proteoglycan sulfation\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetics linked to active-site residues, replicated across multiple unrelated families, corroborated by prior mouse KO data\",\n      \"pmids\": [\"21549340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Recombinant gPAPP (BPNT2) was used to couple sulfotransferase reactions in vitro by releasing the 3'-phosphate from PAP, enabling determination of enzyme kinetics (Michaelis-Menten constants) and demonstrating PAP product inhibition removal for sulfotransferases. This confirms gPAPP specifically acts as a PAP 3'-phosphatase and its enzymatic rate is quantifiable for coupled assay design.\",\n      \"method\": \"In vitro enzyme kinetics assay (malachite green phosphate detection), radioisotope validation assay, coupled enzyme reaction with recombinant gPAPP\",\n      \"journal\": \"Analytical biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with kinetic characterization and orthogonal radioisotope validation, single lab\",\n      \"pmids\": [\"22289690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The catalytic activity of BPNT2 is required for GAG sulfation in vitro: a catalytic-dead Bpnt2 construct (D108A) fails to rescue impaired intracellular and secreted sulfated GAGs (including chondroitin-4-sulfate) in Bpnt2-KO mouse embryonic fibroblasts. Human chondrodysplasia-causing missense mutations adjacent to the catalytic site recapitulate GAG sulfation defects in MEFs. Lithium inhibits GAG sulfation in a BPNT2-dependent manner.\",\n      \"method\": \"Catalytic-dead mutagenesis (D108A) rescue experiment in Bpnt2-KO MEFs, disease-associated missense mutation functional assay, lithium treatment of MEFs with GAG sulfation quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — active-site mutagenesis with functional rescue assay, disease mutation validation, chemical inhibitor corroboration; single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"34634304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IMPAD1 (BPNT2) drives lung cancer invasion and metastasis by enhancing Golgi-mediated secretion; this pro-invasive effect is suppressed by therapeutically inhibiting matrix metalloproteases (MMPs), placing IMPAD1-mediated Golgi secretion upstream of MMP-dependent invasion.\",\n      \"method\": \"Gain-of-function invasion screen, in vitro invasion assays, in vivo metastasis models, MMP inhibitor treatment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function screen validated by in vitro and in vivo assays with pharmacological epistasis (MMP inhibitor), single lab\",\n      \"pmids\": [\"32753652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IMPAD1 (BPNT2) promotes lung cancer metastasis by inhibiting mitochondrial Complex I activity, reducing mitochondrial ROS levels, and increasing intracellular AMP, which activates the AMPK-Notch1-HEY1 signaling pathway. AMP acts as an ADORA1 agonist, and ADORA1 inhibition reduces pAMPK and HEY1 expression in IMPAD1-overexpressing cells.\",\n      \"method\": \"IMPAD1 knockdown and overexpression in vitro/in vivo, mitochondrial Complex I activity assay, ROS measurement, pAMPK/Notch1/HEY1 western blotting, ADORA1 inhibitor treatment\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays (Complex I, ROS, signaling pathway), pharmacological epistasis, but non-canonical function contradicts established Golgi-PAP hydrolysis role; single lab\",\n      \"pmids\": [\"32417395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Impad1 is a direct transcriptional target of the epithelial miRNAs miR-200 and miR~96, which suppress its expression; it is de-repressed during epithelial-to-mesenchymal transition (EMT). Impad1 modulates Golgi apparatus morphology and vesicular trafficking through a direct interaction with the trafficking protein Syt11, altering the extracellular matrix and tumor microenvironment to promote invasion and metastasis. Inhibiting either Impad1 or Syt11 disrupts the cancer cell secretome and reverses the invasive phenotype.\",\n      \"method\": \"miRNA target validation (miR-200/miR-96), co-immunoprecipitation or interaction assay with Syt11, Golgi morphology imaging, secretome analysis, in vitro invasion assays, in vivo metastasis models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — miRNA regulation validated, protein-protein interaction identified, Golgi morphology and secretome measured; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36170810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IMPAD1 (gPAPP/BPNT2) converts PAP to AMP in vitro, enabling coupling to the AMP-Glo bioluminescence detection system to measure sulfotransferase activities; this confirms PAP-to-AMP conversion as the specific enzymatic activity of IMPAD1.\",\n      \"method\": \"Enzyme-coupled in vitro biochemical assay using recombinant IMPAD1 to convert PAP to AMP, bioluminescent detection\",\n      \"journal\": \"Assay and drug development technologies\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro enzymatic reconstitution, single lab, single method\",\n      \"pmids\": [\"29120675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BPNT2 participates in a mammalian rapid tRNA decay (mRTD) pathway for tRNA quality control under heat stress, alongside Bpnt1 and Xrn1/Xrn2 exonucleases; intracellular pAp level control by Bpnt1/Bpnt2 is required for selective degradation of tRNALeu(CAG) under heat stress.\",\n      \"method\": \"Genetic deletion of Thumpd1 in NIH/3T3 cells, tRNA decay assays under heat stress, measurement of pAp levels, pathway epistasis with Xrn1/Xrn2\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic epistasis with defined molecular pathway in mammalian cells, but BPNT2 is one of two closely related enzymes implicated collectively; single lab\",\n      \"pmids\": [\"40595590\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BPNT2 (gPAPP/IMPAD1) is a Golgi-resident, magnesium-dependent, lithium-inhibited 3'-phosphatase that hydrolyzes PAP (3'-phosphoadenosine 5'-phosphate), the sulfotransferase byproduct, to AMP, thereby clearing product inhibition within the Golgi to sustain glycosaminoglycan (particularly chondroitin-4-sulfate) sulfation; loss of its catalytic activity—whether by genetic KO, catalytic-dead mutation (D108A), disease-causing missense mutations, or lithium inhibition—impairs GAG sulfation and causes skeletal dysplasia, while in cancer contexts BPNT2 also modulates Golgi morphology and vesicular secretion through interaction with Syt11, is regulated by miR-200/miR-96 during EMT, and has additionally been implicated in a mammalian tRNA quality-control decay pathway.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BPNT2 (gPAPP/IMPAD1) is a Golgi-resident, magnesium-dependent, lithium-inhibited 3'-phosphatase that hydrolyzes 3'-phosphoadenosine 5'-phosphate (PAP)—the byproduct of sulfotransferase reactions—to AMP, thereby relieving product inhibition and sustaining glycosaminoglycan sulfation [#0, #2, #7]. This catalytic activity is essential for GAG sulfation: a catalytic-dead D108A construct fails to rescue intracellular and secreted sulfated GAGs (including chondroitin-4-sulfate) in Bpnt2-KO fibroblasts, and lithium inhibits sulfation in a BPNT2-dependent manner [#3]. Loss of this function is physiologically consequential—murine inactivation produces neonatal lethality, dwarfism, aberrant cartilage, and undersulfated chondroitin [#0], and homozygous active-site missense mutations in humans cause chondrodysplasia with brachydactyly, joint dislocations, cleft palate, and facial dysmorphism, with disease alleles recapitulating the GAG defect in cells [#1, #3]. Beyond its canonical sulfation role, BPNT2 drives lung cancer invasion and metastasis by enhancing Golgi-mediated secretion upstream of MMP-dependent invasion, acting through a direct interaction with the trafficking protein Syt11 to remodel Golgi morphology and the secretome, and is de-repressed during EMT upon loss of miR-200/miR-96 suppression [#4, #6]. BPNT2-dependent control of intracellular PAP levels has additionally been implicated in a mammalian rapid tRNA decay pathway under heat stress, acting alongside Bpnt1 and Xrn1/Xrn2 [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Establishing where PAP, the inhibitory sulfotransferase byproduct, is cleared and why it matters answered whether a dedicated Golgi enzyme links nucleotide turnover to glycosaminoglycan sulfation.\",\n      \"evidence\": \"Mouse knockout with GAG sulfation biochemistry, subcellular localization, and in vitro lithium inhibition assay\",\n      \"pmids\": [\"18695242\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of catalysis and lithium sensitivity not resolved\", \"Mechanism connecting undersulfation to skeletal phenotype not detailed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Whether BPNT2 catalytic function is required in humans was answered by linking active-site mutations to a defined skeletal disease.\",\n      \"evidence\": \"Whole-exome sequencing of affected families with active-site mutation identification, corroborated by mouse KO data\",\n      \"pmids\": [\"21549340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype severity correlation across mutations not established\", \"Direct enzymatic deficit of patient alleles not measured in this study\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Reconstituting the enzyme in vitro confirmed PAP-3'-phosphatase identity and quantified its kinetics, enabling its use to relieve product inhibition of sulfotransferases.\",\n      \"evidence\": \"In vitro coupled enzyme kinetics with malachite green phosphate detection and radioisotope validation\",\n      \"pmids\": [\"22289690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate specificity relative to related phosphatases not delineated\", \"In-cell kinetics not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"An orthogonal assay coupling PAP-to-AMP conversion confirmed AMP as the reaction product and supported sulfotransferase activity measurement.\",\n      \"evidence\": \"Enzyme-coupled bioluminescent (AMP-Glo) assay with recombinant IMPAD1\",\n      \"pmids\": [\"29120675\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single method, single lab\", \"No new physiological insight beyond confirming product identity\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Whether BPNT2 has roles beyond skeletal biology was addressed by showing it promotes lung cancer invasion via Golgi secretion upstream of MMPs.\",\n      \"evidence\": \"Gain-of-function invasion screen, in vitro/in vivo metastasis assays, MMP inhibitor epistasis\",\n      \"pmids\": [\"32753652\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether catalytic activity is required for the pro-invasive effect not tested\", \"Direct secreted cargoes not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A metabolic-signaling axis for IMPAD1 in cancer was proposed, linking AMP accumulation to AMPK-Notch1-HEY1 signaling and Complex I inhibition.\",\n      \"evidence\": \"Knockdown/overexpression with Complex I activity, ROS, signaling western blots, and ADORA1 inhibitor treatment\",\n      \"pmids\": [\"32417395\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Non-canonical mechanism diverges from the established Golgi-PAP hydrolysis role and not independently confirmed\", \"Direct mechanism by which a Golgi phosphatase inhibits mitochondrial Complex I unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The trafficking mechanism and upstream regulation of IMPAD1 in cancer were defined through a direct Syt11 interaction and miR-200/miR-96 control during EMT.\",\n      \"evidence\": \"miRNA target validation, Syt11 interaction assay, Golgi morphology imaging, secretome analysis, in vitro/in vivo metastasis models\",\n      \"pmids\": [\"36170810\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the Syt11 interaction depends on BPNT2 catalytic activity not resolved\", \"Structural details of the BPNT2-Syt11 interface unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A new role for BPNT2 in RNA quality control was identified, implicating PAP-level control in heat-stress tRNA decay.\",\n      \"evidence\": \"Thumpd1 deletion in NIH/3T3 cells, tRNA decay assays under heat stress, pAp measurement, Xrn1/Xrn2 pathway epistasis\",\n      \"pmids\": [\"40595590\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"BPNT2 implicated collectively with Bpnt1, so its individual contribution is unresolved\", \"Mechanistic link between PAP levels and selective tRNA degradation not detailed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether the Golgi sulfation function, the secretory/Syt11 cancer function, and the tRNA-decay function reflect one unified PAP-clearing activity or distinct catalysis-independent roles remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of the human enzyme reported in the corpus\", \"Catalytic dependence of the cancer and tRNA-decay roles not directly tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 3, 7]},\n      {\"term_id\": \"GO:0016791\", \"supporting_discovery_ids\": [0, 2, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [4, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"SYT11\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}